Trial Profile
An Open Label, Phase I Trial of Intravenous Administration of Volasertib as Monotherapy and in Combination With Azacitidine in Patients With Myelodysplastic Syndrome After Hypomethylating Agents Treatment Failure
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2022
Price :
$35
*
At a glance
- Drugs Volasertib (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 May 2022 Results of a pooled analysis of which summarized three phase I studies (NCT01957644,NCT02201329 and NCT02721875) published in the BMC Cancer
- 19 Dec 2016 Status changed from recruiting to discontinued.
- 06 Sep 2016 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.